Evidence map›Paper›PMID 40400457›Full record

ArticleEuropean heart journal2025

Prediction of ventricular arrhythmic outcomes in suspected cardiac sarcoidosis: a comparison of cardiovascular magnetic resonance phenotyping vs. societal recommendations for implantable cardioverter-defibrillator placement.

Harold Mathijssen, Parag H Bawaskar, Yogita Rochlani, Issac Georgy, Pal Satyajit Singh Athwal, Yugene Guo, Daniel Pollmann, Jeremy Markowitz, Lisa Von Wald, Henri Roukoz and 13 more

Abstract readMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Harold MathijssenDepartment of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.
Parag H BawaskarCardiovascular Division, Department of Medicine, University of Minnesota Medical School, 420 Delaware Street SE, MMC 508, Minneapolis, MN 55455, USA.
Yogita RochlaniDivision of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Issac GeorgyCardiovascular Division, Department of Medicine, University of Minnesota Medical School, 420 Delaware Street SE, MMC 508, Minneapolis, MN 55455, USA.
Pal Satyajit Singh AthwalCardiovascular Division, Department of Medicine, University of Minnesota Medical School, 420 Delaware Street SE, MMC 508, Minneapolis, MN 55455, USA.
Yugene GuoCardiovascular Division, Department of Medicine, University of Minnesota Medical School, 420 Delaware Street SE, MMC 508, Minneapolis, MN 55455, USA.
Daniel PollmannCardiovascular Division, Department of Medicine, University of Minnesota Medical School, 420 Delaware Street SE, MMC 508, Minneapolis, MN 55455, USA.
Jeremy MarkowitzCardiovascular Division, Department of Medicine, University of Minnesota Medical School, 420 Delaware Street SE, MMC 508, Minneapolis, MN 55455, USA.
Lisa Von WaldCardiovascular Division, Department of Medicine, University of Minnesota Medical School, 420 Delaware Street SE, MMC 508, Minneapolis, MN 55455, USA.
Henri RoukozCardiovascular Division, Department of Medicine, University of Minnesota Medical School, 420 Delaware Street SE, MMC 508, Minneapolis, MN 55455, USA.
David PerlmanDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA.
Maneesh BhargavaDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA.
Leandro SlipczukDivision of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID 0000-0003-3091-3735
Annalisa FiltzDivision of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Julio Andres Ovalle RamosDivision of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Saurabhi SamantDivision of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Sanya ChhikaraCardiovascular Division, Department of Medicine, University of Minnesota Medical School, 420 Delaware Street SE, MMC 508, Minneapolis, MN 55455, USA.ORCID 0000-0002-3950-6290
Francesco CastagnaDivision of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Marcel VeltkampDepartment of Pulmonology, St. Antonius Hospital, Nieuwegein, The Netherlands.
Fatima AkdimDepartment of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.
Annelies L M BakkerDepartment of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.
Marco C PostDepartment of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.
Chetan ShenoyCardiovascular Division, Department of Medicine, University of Minnesota Medical School, 420 Delaware Street SE, MMC 508, Minneapolis, MN 55455, USA.ORCID 0000-0001-8877-4999

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
Predictive Models of Beryllium Sensitization and Chronic Beryllium DiseaseR01ES034767 · NIEHS · NATIONAL JEWISH HEALTH · PI Maneesh Bhargava, Li Li · 2023 to 2026
$3.2M
Molecular Characterization of Progressive Pulmonary SarcoidosisR01HL162955 · NHLBI · NATIONAL JEWISH HEALTH · PI Maneesh Bhargava, ELLIOTT D CROUSER · 2023 to 2026
$3.2M
Comprehensive Proteomic Classifier for the Molecular Characterization of Pulmonary SarcoidosisR01HL153613 · NHLBI · UNIVERSITY OF MINNESOTA · PI BHARGAVA, MANEESH, MAIER, LISA A · 2021 to 2024
$2.8M
Immunologic basis of cardiac disease after severe COVID-19R01HL158756 · NHLBI · UNIVERSITY OF MINNESOTA · PI BAKER, JASON V, SHENOY, CHETAN · 2022 to 2025
$2.7M
Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related CardiotoxicityK23HL132011 · NHLBI · UNIVERSITY OF MINNESOTA · PI SHENOY, CHETAN N · 2016 to 2020
$884k
A Myocardial Approach to Identify the Cause of CardiomyopathyR21HL172296 · NHLBI · UNIVERSITY OF MINNESOTA · PI SHENOY, CHETAN · 2024 to 2025
$233k
Cardiac Magnetic Resonance Imaging Guided Risk Stratification in Cardiac SarcoidosisR03HL157011 · NHLBI · UNIVERSITY OF MINNESOTA · PI SHENOY, CHETAN N · 2021 to 2022
$155k
NHLBI NIH HHS R21 HL172296NIH HHS K23HL132011NIH HHS KL2TR000113-05NIH HHS R01ES034767NIH HHS R01HL153613NIH HHS R01HL158756NIH HHS R01HL162955NIH HHS R03HL157011NIH HHS R21HL172296NIH HHS UL1TR002494University of Minnesota Clinical and Translational Science Institute KL2 Scholars Career Development Program AwardUniversity of Minnesota Clinical and Translational Science Institute K-R01 Transition to Independence
6 · The paper itself

Abstract

BACKGROUND AND

aimsImplementing societal recommendations for primary prevention implantable cardioverter-defibrillators (ICDs) in cardiac sarcoidosis requires an accurate diagnosis. However, cardiac sarcoidosis diagnostic schemes are inconsistent and often produce conflicting results. This study aimed to compare the discriminative accuracy of cardiovascular magnetic resonance imaging (CMR) phenotyping with the societal recommendations for predicting long-term ventricular arrhythmic outcomes in patients with suspected cardiac sarcoidosis, regardless of their diagnostic status.

methodsThis multicentre study included patients with histology-supported sarcoidosis who underwent CMR for suspected cardiac involvement and were ineligible for secondary prevention ICDs. The study outcome was a composite of fatal or life-threatening ventricular arrhythmias. Outcomes were compared based on eligibility for ICDs by societal recommendations and CMR phenotyping.

resultsAmong 1514 patients, 84 experienced the study outcome during a median follow-up of 4.5 years and a maximum follow-up of 10 years. The high-risk CMR phenotype was associated with higher 5- and 10-year incidences of the outcome (24.0% and 35.0%, respectively) compared with those who met societal recommendations. Patients with low-risk phenotypes had lower incidences (0.7% and 2.6%). Cardiovascular magnetic resonance imaging phenotyping outperformed societal recommendations in discriminative accuracy, with areas under the curve of 0.861 and 0.776 for 5- and 10-year outcomes, respectively. Additionally, CMR phenotyping had the highest adjusted subdistribution hazard ratio (19.8) for the study outcome.

conclusionsIn patients with suspected cardiac sarcoidosis, CMR phenotyping showed greater discriminative accuracy than societal recommendations for predicting fatal or life-threatening ventricular arrhythmias, suggesting that it may be more effective at identifying candidates for primary prevention ICDs.

Indexed as

Arrhythmias, CardiacCardiomyopathiesDefibrillators, ImplantableSarcoidosisTachycardia, VentricularAgedDeath, Sudden, CardiacFemaleHumansMagnetic Resonance ImagingMagnetic Resonance Imaging, CineMaleMiddle AgedPhenotypePractice Guidelines as TopicCardiac sarcoidosisCardiovascular magnetic resonance imagingICD decision-makingPrimary preventionRisk stratification

Identifiers

PMID40400457
PMCPMC12450518

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.